Nova abordagem terapéutica para dislpidemias: PCSK9

Abstract

Cardiovascular diseases (CVD) are among many other diseases that strongly put to death people all over the world. In developing countries, including Brazil, the mortality caused by cardiovascular complication has shown quickly substantial elevations. According to WHO (World Health Organization), these increases tendency of prevalence of cardiovascular diseases in the country tend to remain, aggravating even more the figures of morbidity and mortality. The formation of atherosclerotic plaque is the most of time responsible for the occurrence of CVD. Among the mainrisk component to atherosclerosis there are dyslipidemias with changes in serum concentrations of lipoproteins. Dyslipidemias are generally treated with lipid-lowering drugs. Statins and Fibrates are the first choice drugs indicated for the treatment. However, several epidemiologic studies have shown that a great number of patients are not adequately treated with up-to-date medicine. Consequently, this practice may create therapeutic gaps, stimulating pharmacological research in order to obtain new lipid-lowering medication. One of the great apexes of these research was to associate this pro-protein subtilisin kexin type 9 (PCSK9) function into metabolism of lipid. From this association several phases II and III studies evaluated medications that inhibit this protein action resulting in increased the lipid levels.